• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Alkermes

edit

Alkermes, Inc. is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. Alkermes, Inc. develops, manufactures and commercializes VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar I disorder. Its pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system (CNS), disorders, reward disorders, addiction, diabetes and autoimmune disorders. The Company has a research facility in Massachusetts and a commercial manufacturing facility in Ohio. RISPERDAL CONSTA is used for the treatment of schizophrenia and for the treatment of bipolar I disorder. VIVITROL is an extended-release MEDISORB formulation of naltrexone, as a once-monthly injectable medication for the treatment of alcohol dependence.

Recent Milestones

edit

• 
  Alkermes — returned positive results from its Phase 1b study of ALKS 9070, its treatment for schizophrenia (6/30/11)
  Posted 6/30/11 at 10:23am via masshightech.com
• 
  Alkermes — acquiring the Elan Drug Technologies unit of Ireland’s Elan Corp. plc in a cash and stock merger deal worth approximately $960 million that will see Alkermes Inc. relocate its headquarters officially to Dublin, Ireland, and become Alkermes plc (5/9/11)
  Posted 5/10/11 at 3:01am via masshightech.com
• 
  Alkermes — Alkermes buys Elan's delivery unit in $960M buyout deal (5/9/11)
  Posted 5/9/11 at 6:37pm via fiercebiotech.com
• 
  Went public with stock symbol NASDAQ:ALKS.
  Posted 5/9/11 at 6:36pm
• 
  Alkermes added Richard F. Pops as Chairman and CEO.
  Posted 5/9/11 at 6:34pm
• 
  Alkermes added Shane Cooke as President.
  Posted 3/9/13 at 3:52am
• 
  Alkermes added Cheryl Larrivee-Elkins as VP of Regulatory Affairs.
  Posted 4/16/13 at 2:27am

Videos

Screenshots

edit

Above: Alkermes
Uploaded: 3/9/13

Stock Price

Sources

Alkermes buys Elan's delivery unit in $960M buyout deal (fiercebiotech.com) [edit]
Alkermes buying Elan drug unit, changing HQ location to Dublin (masshightech.com) [edit]
Alkermes' schizophrenia treatment hits on positive data (masshightech.com) [edit]